Navigation Links
genae Appoints Chief Medical Officer
Date:4/16/2012

ANTWERP, Belgium, April 16, 2012 /PRNewswire/ --

genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services.

"I am delighted to welcome Catalina, whose extensive clinical and research expertise will be of great benefit to the many aspects of our services offering," said Bart Segers, Chairman and CEO of genae. "We believe that her experience as an interventional cardiologist provides her with a unique opportunity to view our services with an unsurpassed balance of clinical insight, business acumen and regulatory and safety compliance.

Dr. Trana holds the position of Cardiology Specialist at the Interventional Cardiology Department of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She was a fellow at the Cardiovascular Center Aalst, OLVZ, Aalst, Belgium and worked and trained at the Interventional Cardiology Department and Cardiovascular Surgical Department of the Cardiovascular Center in Iasi, Romania; and at the Catholic University of Leuven, Belgium. Her scientific and research work is illustrated by peer-reviewed publications and presentations during international congresses and symposia.

About genae

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for Clinical Trial Management, Core Laboratory Services and Additional Services for the Medical Industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium.

genae Americas Inc. is a privately held company with principal offices in Cleveland, OH.

Please visit: http://www.genae.com

Company Contact

genae associates nv
Justitiestraat 6B
2018 Antwerp, Belgium
Aly Talen, RN
Sr. VP Business Development
+32-3-290-03-06
aly.talen@genae.com

genae Americas Inc.
Global Cardiovascular Innovation Center
10000 Cedar Avenue
Cleveland, OH 44106, USA
Dimitri Buytaert, PT CCRA
President
+1-216-445-4535
dimitri.buytaert@genae.com


'/>"/>
SOURCE genae associates nv
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
2. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
3. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
6. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
Breaking Medicine News(10 mins):